Opdivo Qvantig Prices, Coupons, Copay Cards & Patient Assistance
Opdivo Qvantig (hyaluronidase/nivolumab) is a member of the anti-PD-1 and PD-L1 monoclonal antibodies (immune checkpoint inhibitors) drug class and is commonly used for Colorectal Cancer, Esophageal Carcinoma, Gastric Cancer, and others.
Opdivo Qvantig prices
Subcutaneous Solution
nvhy 10,000 units-600 mg/5 mL Opdivo Qvantig subcutaneous solution from $7,766.70 for 5 milliliters
| Quantity | Per unit | Price |
|---|---|---|
| 5 milliliters | $1,553.34 | $7,766.70 |
Important: When there is a range of pricing, consumers should normally expect to pay the lower price. However, due to stock shortages and other unknown variables we cannot provide any guarantee.
Get your FREE Drugs.com Discount Card
Save up to 80% off the cost of prescription drugs and OTC medicines valid at over 65,000 pharmacies.
This is a drug discount program, not an insurance plan.
Opdivo Qvantig Coupons, Copay Cards and Rebates
Opdivo Qvantig offers may take the form of printable coupons, rebates, savings or copay cards, trial offers, or free samples. Certain offers may be printable from a website while others may require registration, completing a questionnaire, or obtaining a sample from a medical professional.
Opdivo+Qvantig (combo) BMS Access Support Co-Pay Assistance Program
Eligible commercially insured patients may pay as little as $0 per dose; patients must call 800-861-0048 to enroll.
- Applies to:
- Opdivo Qvantig
- Number of uses:
- per prescription per calendar year
Form more information phone: 800-861-0048 or Visit website
Patient Assistance & Copay Programs for Opdivo Qvantig
Patient assistance programs (PAPs) are typically sponsored by pharmaceutical companies and offer cost-free or discounted medicines, as well as copay programs, to individuals with low income or those who are uninsured/under-insured and meet specific criteria. Eligibility requirements for each program may vary.
Provider: Patient Access Network Foundation (PAN)
Eligibility requirements:- *See Additional Information section below
- Between 400-500% of FPL
- FDA Approved Diagnosis - See Program Website for Details
- Must reside and receive treatment in US
- *Patients must have health insurance and their insurance must cover the qualifying medication for which they seek assistance. Call for most recent medications as the list is subject to change and the medication for which you are seeking assistance must treat the disease directly. Note: All new enrollment is now done electronically or over the phone. Contact program for details.
- Opdivo Qvantig (nivolumab-hyaluronidase-nvhy) Injection; Subcutaneous
More information please phone: 866-316-7263 Visit website
Provider: Bristol Myers Squibb (BMS) Access Support
Eligibility requirements:- Contact program for details.
- Not disclosed
- Medically Necessary as determined by a Doctor
- Must be residing in the US or Puerto Rico
- *This program provides the screening for the Bristol-Myers Squibb Patient Assistance Foundation (BMSPAF) Oncology Patient Assistance Program. Co-payment assistance, patient support, and patient assistance programs are available for eligible patients. Please refer to the Enrollment Form to ensure the correct Fax number and address is used for your medication.
- Opdivo Qvantig (nivolumab-hyaluronidase-nvhy) Injection; Subcutaneous
More information please phone: 800-861-0048 Visit website
Disclaimer: Medication pricing is sourced from a variety of providers. Pricing may vary significantly due to several factors including brand or generic status, insurance coverage, pharmacy choice, location, and manufacturer pricing policies. Prices are subject to change. For the most accurate and up-to-date information, always consult directly with your pharmacy or healthcare provider.
See also:
More about Opdivo Qvantig (hyaluronidase / nivolumab)
- Check interactions
- Compare alternatives
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: anti-PD-1 and PD-L1 monoclonal antibodies (immune checkpoint inhibitors)
- En español